Research programme: cancer therapeutics - EsperanceAlternative Names: EP-302
Latest Information Update: 16 Jul 2016
At a glance
- Originator Esperance Pharmaceuticals
- Class Peptides
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer